Literature DB >> 33960573

Meflin defines mesenchymal stem cells and/or their early progenitors with multilineage differentiation capacity.

Akitoshi Hara1,2, Katsuhiro Kato2, Toshikazu Ishihara1,2, Hiroki Kobayashi1, Naoya Asai3, Shinji Mii1, Yukihiro Shiraki1, Yuki Miyai1, Ryota Ando1, Yasuyuki Mizutani1, Tadashi Iida1, Mikito Takefuji2, Toyoaki Murohara2, Masahide Takahashi4, Atsushi Enomoto1.   

Abstract

Mesenchymal stem cells (MSCs) are the likely precursors of multiple lines of mesenchymal cells. The existence of bona fide MSCs with self-renewal capacity and differentiation potential into all mesenchymal lineages, however, has been unclear because of the lack of MSC-specific marker(s) that are not expressed by the terminally differentiated progeny. Meflin, a glycosylphosphatidylinositol-anchored protein, is an MSC marker candidate that is specifically expressed in rare stromal cells in all tissues. Our previous report showed that Meflin expression becomes down-regulated in bone marrow-derived MSCs cultured on plastic, making it difficult to examine the self-renewal and differentiation of Meflin-positive cells at the single-cell level. Here, we traced the lineage of Meflin-positive cells in postnatal and adult mice, showing that those cells differentiated into white and brown adipocytes, osteocytes, chondrocytes and skeletal myocytes. Interestingly, cells derived from Meflin-positive cells formed clusters of differentiated cells, implying the in situ proliferation of Meflin-positive cells or their lineage-committed progenitors. These results, taken together with previous findings that Meflin expression in cultured MSCs was lost upon their multilineage differentiation, suggest that Meflin is a useful potential marker to localize MSCs and/or their immature progenitors in multiple tissues.
© 2021 The Authors. Genes to Cells published by Molecular Biology Society of Japan and John Wiley & Sons Australia, Ltd.

Entities:  

Keywords:  Islr; Meflin; Mesenchymal stem cells; Mesenchymal stromal cells; immunoglobulin superfamily containing leucine-rich repeat; satellite cell

Year:  2021        PMID: 33960573     DOI: 10.1111/gtc.12855

Source DB:  PubMed          Journal:  Genes Cells        ISSN: 1356-9597            Impact factor:   1.891


  5 in total

1.  Pharmacologic conversion of cancer-associated fibroblasts from a protumor phenotype to an antitumor phenotype improves the sensitivity of pancreatic cancer to chemotherapeutics.

Authors:  Tadashi Iida; Yasuyuki Mizutani; Nobutoshi Esaki; Suzanne M Ponik; Brian M Burkel; Liang Weng; Keiko Kuwata; Atsushi Masamune; Seiichiro Ishihara; Hisashi Haga; Kunio Kataoka; Shinji Mii; Yukihiro Shiraki; Takuya Ishikawa; Eizaburo Ohno; Hiroki Kawashima; Yoshiki Hirooka; Mitsuhiro Fujishiro; Masahide Takahashi; Atsushi Enomoto
Journal:  Oncogene       Date:  2022-04-13       Impact factor: 8.756

2.  Meflin-positive cancer-associated fibroblasts enhance tumor response to immune checkpoint blockade.

Authors:  Yuki Miyai; Daisuke Sugiyama; Tetsunari Hase; Naoya Asai; Tetsuro Taki; Kazuki Nishida; Takayuki Fukui; Toyofumi Fengshi Chen-Yoshikawa; Hiroki Kobayashi; Shinji Mii; Yukihiro Shiraki; Yoshinori Hasegawa; Hiroyoshi Nishikawa; Yuichi Ando; Masahide Takahashi; Atsushi Enomoto
Journal:  Life Sci Alliance       Date:  2022-03-02

Review 3.  Good and Bad Stroma in Pancreatic Cancer: Relevance of Functional States of Cancer-Associated Fibroblasts.

Authors:  Ryota Ando; Akihiro Sakai; Tadashi Iida; Kunio Kataoka; Yasuyuki Mizutani; Atsushi Enomoto
Journal:  Cancers (Basel)       Date:  2022-07-07       Impact factor: 6.575

4.  Matrix remodeling-associated protein 8 is a marker of a subset of cancer-associated fibroblasts in pancreatic cancer.

Authors:  Ryosuke Ichihara; Yukihiro Shiraki; Yasuyuki Mizutani; Tadashi Iida; Yuki Miyai; Nobutoshi Esaki; Akira Kato; Shinji Mii; Ryota Ando; Masamichi Hayashi; Hideki Takami; Tsutomu Fujii; Masahide Takahashi; Atsushi Enomoto
Journal:  Pathol Int       Date:  2022-01-12       Impact factor: 2.121

Review 5.  Possible disease-protective roles of fibroblasts in cancer and fibrosis and their therapeutic application.

Authors:  Yukihiro Shiraki; Shinji Mii; Nobutoshi Esaki; Atsushi Enomoto
Journal:  Nagoya J Med Sci       Date:  2022-08       Impact factor: 0.794

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.